---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-22-002543"
form_type: "8-K"
ticker: "KNSA"
cik: "0001730430"
company_name: "Kiniksa Pharmaceuticals International, plc"
filed_at: "2022-01-10T23:59:59+00:00"
generated_at: "2026-06-27T19:31:18.668012+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Kiniksa reports ~$182M year-end cash sufficient into 2024; mavrilimumab Phase 3 fails; pipeline updates

## Summary
- Preliminary year-end 2021 cash, cash equivalents and short-term investments of ~$182M (unaudited), expected to fund operations into 2024.
- Mavrilimumab Phase 3 in COVID-19 ARDS did not meet primary endpoint; company evaluating next steps.
- Full-year 2022 ARCALYST net revenue guidance to be provided with Q4 and full-year 2021 financial results.
- Vixarelimab Phase 2b data in prurigo nodularis expected in second half of 2022.
- KPL-404 Phase 2 trial in rheumatoid arthritis now enrolling and dosing patients.

## SEC filing metadata
- accession: 0001104659-22-002543
- form_type: 8-K
- ticker: KNSA
- cik: 0001730430
- company_name: Kiniksa Pharmaceuticals International, plc
- filed_at: 2022-01-10T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1730430/000110465922002543/0001104659-22-002543-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1730430/000110465922002543/tm222297d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-22-002543
- JSON: https://secwatch.observer/filing/0001104659-22-002543.json
- Plain text: https://secwatch.observer/filing/0001104659-22-002543.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.